The New York Times recently ran a story that paints an inaccurate picture of the 340B program, contract pharmacy participation in the program and the biopharmaceutical industry’s commitment to the program. Today, we’re correcting the record.
Fact: Manufacturers are still giving the 340B discounts, as required by law, to “covered entities” – more than 12,700 hospitals and clinics currently participating in the 340B program. Some companies have recently implemented changes to shipment of 340B drugs in response to decades of program failures, which is being mischaracterized by some. These companies are still providing discounts to 340B covered entities, but in some cases not to offsite pharmacies that were never included in the program to begin with when Congress created 340B.
Fact: The biopharmaceutical industry fully supports the program and has supported the program since it first became law in 1992. In comments submitted just last month to Representative Greg Walden and Senator Lamar Alexander on ways to improve the program, PhRMA stated:
“We look forward to continuing our conversations on meaningful improvements that can be made to ensure the 340B program is overseen and operated in a way that sustains the program for the long-term so that patients more directly benefit from the discounts provided by biopharmaceutical manufacturers. PhRMA and our member companies have long supported the 340B program and the critical safety-net role it was intended to play in our nation’s health care system.”
Fact: Despite 4,000% growth in contract pharmacy participation in the program, there is no clear evidence 340B hospitals and their contract pharmacies always or even usually help needy patients access medicines. In fact, the GAO report found that less than half of hospitals surveyed provide 340B discounts to low-income, uninsured patients at some or all their contract pharmacies. Since patients are currently not getting access to the 340B discount in most cases, limiting shipment of 340B discounted medicines to covered entities or to fewer contract pharmacies would appear to have very little impact on patient access or affordability.
Fact: The program was created to support qualifying nonprofit hospitals and safety-net clinics, not corporate companies like Walgreens and CVS. Despite this, there are more than 28,000 contract pharmacies today, most of which are chain pharmacies. In fact, GAO found that “the five biggest pharmacy chains—CVS, Walgreens, Walmart, Rite-Aid, and Kroger—represented a combined 60 percent of 340B contract pharmacies, but only 35 percent of all pharmacies nationwide.” These large corporations are some of the most profitable in the country, yet they are siphoning the discounts provided by manufacturers away from patients.
Fact: Contract pharmacies were never authorized by Congress. They were born out of 10-year old guidance issued from the Health Resources and Services Administration (HRSA). This guidance had the unintended consequence of opening the doors for thousands of corporate pharmacies to profit off a program that was never intended to be a revenue stream for them. Even the government has said agency guidance cannot impose any binding requirements on the public and lacks the force and effect of law.
As we fight a global pandemic that is having a disproportionate impact on vulnerable patients, it has never been more important for policymakers to ensure federal programs like 340B are benefiting the low-income and uninsured individuals the program was intended to serve. Unfortunately, the program has strayed far off course, with documented evidence of program abuse by covered entities and patients not benefiting.
Just this week, a new GAO report found that for HRSA audits in FY 2012-2019, there were more than 1,500 findings of noncompliance by covered entities with 340B requirements. HRSA told GAO that beginning in Fall 2019 “it would no longer issue findings based solely on noncompliance with guidance” and acknowledged that “the 340B statute does not provide criteria for determining patient eligibility.” Similarly, HRSA is looking the other way at noncompliance with contract pharmacy oversight “because the 340B statute does not address contract pharmacy use.” Clearly this program is fraught with problems if even HRSA is acknowledging it cannot enforce compliance with program requirements.
To get the program back on track, we need to have a fully informed and honest conversation about what is working and not working, as well as real solutions that will help patients. Incomplete pictures that mischaracterize the 340B program only make efforts to improve the program for patients harder.
Nicole Longo
Nicole Longo is Deputy Vice President of public affairs at PhRMA focusing on Medicare, 340B, importation and more. She previously worked for a D.C.-based public affairs firm where she assisted a wide range of clients with communications efforts on everything from trade policy to agriculture policy to health care policy. Outside the office, Nicole can be found trying new restaurants (usually Italian), taking an occasional barre class and cheering on the Cincinnati Bengals.
Nicole Longo
Employers faced $12.8 billion in higher costs due to 340B in 2025
New Report: Hospitals, clinics and for-profit partners pocketed $142B in 2025 from 340B
Hospitals are hiding information that could lower costs for patients
As football season kicks off, hospitals keep scoring on 340B
ICYMI: Hospital consolidation is driving up health care costs
It's time to modernize 340B: The case for a rebate model
ICYMI: Fox business hosts call 340B a ‘Rotten System’ and ‘Cash Cow’ for hospitals
340B’s reality: A booming business for hospitals, pharmacies and corporate giants
340B’s lack of guardrails lets big hospital systems turn it into an oversight-free revenue stream
Private equity's new play? Become a nonprofit to profit off 340B.
340B is growing, but it is unclear if Illinois patients benefit
Fox Business spotlights hospitals abuse of the 340B program
The Wall Street Journal raises new alarms about 340B
Hospitals in the hot seat: Congress sharpens focus on 340B, consolidation and rising costs
New "Goldmine” ad reveals hospitals hide how they profit from 340B markups
A program off track: How 340B drives both hospital consolidation and system gaming
Washington Post Editorial Board says 340B has become “corporate welfare”
Modernizing 340B using rapid verification: The case for a rebate model
Hospitals drive nearly 80% of the U.S. health spending gap
Congress should look under the hood of 340B, hospitals don't want them to
340B hospitals buy low and sell high, a new analysis shows
New report from Minnesota: 340B is generating billions for big hospitals
340B hospital markup scheme is costing states, taxpayers billions
Questions mount over 340B program and increased cost to everyone
PhRMA Forum 2026 highlights the importance of fostering the next era of American leadership
50-state poll says Americans are concerned that hospital markups hurt patients
New analysis finds 340B hospitals push patients toward costly care to boost profits
Data shows tax-exempt hospital profit-seeking behavior, not drug prices, is driving explosive 340B expansion
Big, tax-exempt hospitals are charging cancer patients, employers massive medicine markups
340B’s billion-dollar boom: Oversight lags as spending soars
New study: 340B rebate model pilot won’t hurt cash flow for providers
One thing the Senate can agree on: It’s time to fix 340B
Middlemen mark up drug prices and keep discounts meant for you
The Administration approves manufacturers’ 340B rebate pilot plans
340B abuses are fueling higher Medicare costs, new BRG report shows
ICYMI: The Wall Street Journal calls 340B reform a “good idea to cut drug costs”
340B hospitals use scare tactics to evade accountability
Why states struggle to deliver savings: Middlemen and 340B siphon dollars from patients and states
CBO: 340B program costs taxpayers, no evidence patients benefit
PhRMA stresses importance of 340B Rebate Model Pilot
New “Meet Mark” ad exposes how the 340B hospital markup program drives up costs for everyone
New study unmasks how big-city hospitals exploit 340B by posing as rural providers
Study: 340B hospitals drive up patient drug costs
Curbing 340B abuse and rising costs with the rebate model
The hidden cost of 340B: A multi-billion-dollar burden on taxpayers and Medicaid
Latest analysis from Ohio exposes growing abuses of the 340B markup program
New report finds rampant abuse of the 340B program
How the 340B hospital markup program could hurt Michigan patients
New “Balance the Scales” campaign highlights why Americans pay more for prescription medicines
How the 340B hospital markup program and PBMs drive up costs for U.S. patients
Foreign first pricing schemes don’t address why Americans pay more
When hospitals have free rein to mark up drug prices, who pays the price?
New report finds more abuse of 340B program by hospitals and drug middlemen
A closer look at how health care consolidation drives up patient costs, creates barriers to care
340B markup program is a hidden tax, increasing costs for employers, straining state and federal budgets
New report sheds light on payment flows in the pharmaceutical supply chain, including the role of 340B and vertical integration
Wrapping up the J.P. Morgan Healthcare Conference
NYT exposes hospitals, middlemen make millions off a hospital markup program
PhRMA CEOs Tee Up Next Week's Health Care Conference
New study: Entities that don’t make medicines get half of what is spent on those medicines
A new administration poses new opportunities for patient access
New 340B report from Minnesota exposes steep hospital markups on medicines, patient benefits remain unclear
Michigan hospitals using federal program to markup cost of medicines, gouging patients
340B spending is exploding, forcing prices up for patients, employers and government programs
Three things to know about 340B contract pharmacies
PhRMA urges HRSA not to impede new 340B pricing approaches to improve transparency and integrity
Illegal abuse of 340B hurts us all
340B sales go up, free or reduced-cost care offered at hospitals goes down
ICYMI: Health care policy should be driven by patients, not politics
The hidden bill patients don’t know they are paying
340B grows and grows, but patients do not see the savings
340B grows and grows, but patients do not see the savings
PBMs using 340B program to drive profits at patients’ expense
What’s the 340B program like in your state?
New year, same exploitation of the 340B program
How the 340B program became a PBM giveaway
New report adds to questions about nonprofit status of 340B hospitals
By the Numbers: 340B continues to climb in profits, dwindle with patient support
New 340B Mega Guidance
New report: Hospitals mark up medicine prices 500%
read more
PhRMA responds to Senate: Today’s 340B program leaves patients behind | PhRMA
New studies add to body of evidence questioning 340B efficacy
340B program reaches $100 billion in sales, while patients are left behind
Nonprofit hospitals fall short on community benefit, studies show
Why Congress should prioritize fixing the 340B program
What they are saying: Nonprofit hospitals are gaming the system at the expense of patients
ICYMI: PhRMA kicks off the year at the 2023 J.P. Morgan Health Care Conference
340B program continues to drive shift in care to more expensive hospital settings
The 340B program is interfering with the U.S. biosimilars market and impacting patient costs
Three ways 340B is failing vulnerable patients
If patients aren’t benefiting from the 340B program, who is?
New data: The 340B program is driving up costs for patients and our health care system
Word of the Month: 340B covered entity
340B program remains second largest federal drug program, yet little solid evidence of benefits to patient
Study after study after study: Contract pharmacy expansion not aligned in communities 340B is meant to serve
New research finds gaps in charity care provided by 340B hospitals
New analysis confirms hospitals markup prices for oncology therapies
By the numbers: Contract pharmacy participation in the 340B program
340B 101: Three charts show the program maximizes hospitals’ bottom line with little consideration for patients
New study finds more than half of brand medicine spending goes to the supply chain and others
Making medicines more affordable: Preserving safety-net programs like 340B
Fact Check: Do contract pharmacies help patients access 340B medicines? No.
New video: Why changes to the 340B program are essential for patients
To drive up profits, hospitals continue unnecessary medicine mark-ups, burdening patients, employers and health care system
New analysis adds to research questioning whether 340B is working as Congress intended
340B hospitals among those that provide lowest levels of community benefit across the country
Getting the 340B program back on track in 2021
Fact Check: How hospitals continue to drive health care spending
PhRMA submits comments on ways to refocus the 340B program on America’s vulnerable patients
340B hospitals and for-profit pharmacies generating significant revenue from program meant to help needy patients
Survey found insurance premiums grew faster than inflation in 2020
Growth in 340B program has not translated to improvements for patients
Cancer medicines cost twice as much at hospitals, study finds
New GAO report: Some hospitals participating in 340B may not be eligible for the program
Nearly 50% of brand medicine spending goes to the supply chain and others
New NHE data: Medicine prices declined, and hospitals were biggest driver of health care spending in 2018
Hospitals make 9 times more than physicians’ offices on provider-administered medicines
340B Spotlight: How for-profit middlemen are taking advantage of a program meant to support nonprofit entities and patients
Study finds hospitals continue to mark up medicines up to 500% of their cost
Fresh data show, yet again, 340B is growing while charity care dwindles at many 340B hospitals
New study finds hospitals continue to push patients to costlier outpatient settings
340B continues to drive shift in site of care for physician-administered medicines to more expensive hospital settings
New study finds hospitals prescribe more medicines, and more expensive medicines, after joining 340B program
New study finds some hospitals mark up medicine prices at least 700 percent
New analysis finds 340B medicine sales hit record high in 2017 and continue to grow as a share of total drug spending
PhRMA submission to HHS on blueprint to lower drug prices and reduce out-of-pocket costs
GAO again recommends improvements to 340B program
ICYMI: Analysis finds higher outpatient drug spending at 340B hospitals
New 340B analysis: Hospitals raking in billions while uncompensated care drops by billions
Patients pay the price when hospitals mark up cancer medicines
340B Spotlight: How much money are hospitals pocketing under 340B and what are they doing with those profits?
340B Spotlight: Hospital system adds voice to comments about flawed 340B program
Fact Check Friday: The truth about the cost of 340B to patients
340B Spotlight: New pieces of legislation continue momentum to fix 340B program
340B Spotlight: ICYMI – 340B hearing, new reports highlight growing need for program reform
How much are hospitals marking up the price of medicines? The answer may surprise you.
340B Spotlight: New analysis finds 340B program growth continues to accelerate despite false claims
340B Spotlight: ICYMI – AJC looks at how some Georgia hospitals are profiting off 340B
340B Spotlight: 340B hospitals continue to benefit from consolidation at expense of patients
340B Spotlight: Audit findings show importance of increased oversight of 340B program
Correcting the record: Biopharmaceutical companies remain committed to the 340B program and helping patients
340B
340B Spotlight
Hospitals
Correcting the record: Biopharmaceutical companies remain committed to the 340B program and helping patients
Correcting the record: Biopharmaceutical companies remain committed to the 340B program and helping patients